Cargando…

Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials

SIMPLE SUMMARY: Lung cancer treatment has dramatically evolved in the past decade, but some pitfalls of image interpretation have been introduced in parallel, such as pseudo-progressions. These challenges could be made more evident with blinded independent central reviews, as readers are often blind...

Descripción completa

Detalles Bibliográficos
Autores principales: Beaumont, Hubert, Iannessi, Antoine, Wang, Yi, Voyton, Charles M., Cillario, Jennifer, Liu, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465869/
https://www.ncbi.nlm.nih.gov/pubmed/34572761
http://dx.doi.org/10.3390/cancers13184533
_version_ 1784572986436616192
author Beaumont, Hubert
Iannessi, Antoine
Wang, Yi
Voyton, Charles M.
Cillario, Jennifer
Liu, Yan
author_facet Beaumont, Hubert
Iannessi, Antoine
Wang, Yi
Voyton, Charles M.
Cillario, Jennifer
Liu, Yan
author_sort Beaumont, Hubert
collection PubMed
description SIMPLE SUMMARY: Lung cancer treatment has dramatically evolved in the past decade, but some pitfalls of image interpretation have been introduced in parallel, such as pseudo-progressions. These challenges could be made more evident with blinded independent central reviews, as readers are often blinded to patient clinical symptoms and outcomes. The aim of this study was to analyze a pool of lung trials that used RECIST 1.1, document the proportion of reader discrepancies and the reader performance through monitoring procedures, and provide suggestions for the reduction of read inconsistency. This study provides benchmarks for the reader discordance rate in novel lung cancer therapeutic trials that will help to trigger corrective actions such as initial reader training and follow-up re-training. ABSTRACT: Background: Double reads in blinded independent central reviews (BICRs) are recommended to control the quality of trials but they are prone to discordances. We analyzed inter-reader discordances in a pool of lung cancer trials using RECIST 1.1. Methods: We analyzed six lung cancer BICR trials that included 1833 patients (10,684 time points) involving 17 radiologists. We analyzed the rate of discrepancy of each trial at the time-point and patient levels as well as testing inter-trial differences. The analysis of adjudication made it possible to compute the readers’ endorsement rates, the root causes of adjudications, and the proportions of “errors” versus “medically justifiable differences”. Results: The trials had significantly different discrepancy rates both at the time-point (average = 34.3%) and patient (average = 59.2%) levels. When considering only discrepancies for progressive disease, homogeneous discrepancy rates were found with an average of 32.9%, while readers’ endorsement rates ranged between 27.7% and 77.8%. Major causes of adjudication were different per trial, with medically justifiable differences being the most common, triggering 74.2% of total adjudications. Conclusions: We provide baseline performances for monitoring reader performance in trials with double reads. Intelligent reading system implementation along with appropriate reader training and monitoring are solutions that could mitigate a large portion of the commonly encountered reading errors.
format Online
Article
Text
id pubmed-8465869
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84658692021-09-27 Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials Beaumont, Hubert Iannessi, Antoine Wang, Yi Voyton, Charles M. Cillario, Jennifer Liu, Yan Cancers (Basel) Article SIMPLE SUMMARY: Lung cancer treatment has dramatically evolved in the past decade, but some pitfalls of image interpretation have been introduced in parallel, such as pseudo-progressions. These challenges could be made more evident with blinded independent central reviews, as readers are often blinded to patient clinical symptoms and outcomes. The aim of this study was to analyze a pool of lung trials that used RECIST 1.1, document the proportion of reader discrepancies and the reader performance through monitoring procedures, and provide suggestions for the reduction of read inconsistency. This study provides benchmarks for the reader discordance rate in novel lung cancer therapeutic trials that will help to trigger corrective actions such as initial reader training and follow-up re-training. ABSTRACT: Background: Double reads in blinded independent central reviews (BICRs) are recommended to control the quality of trials but they are prone to discordances. We analyzed inter-reader discordances in a pool of lung cancer trials using RECIST 1.1. Methods: We analyzed six lung cancer BICR trials that included 1833 patients (10,684 time points) involving 17 radiologists. We analyzed the rate of discrepancy of each trial at the time-point and patient levels as well as testing inter-trial differences. The analysis of adjudication made it possible to compute the readers’ endorsement rates, the root causes of adjudications, and the proportions of “errors” versus “medically justifiable differences”. Results: The trials had significantly different discrepancy rates both at the time-point (average = 34.3%) and patient (average = 59.2%) levels. When considering only discrepancies for progressive disease, homogeneous discrepancy rates were found with an average of 32.9%, while readers’ endorsement rates ranged between 27.7% and 77.8%. Major causes of adjudication were different per trial, with medically justifiable differences being the most common, triggering 74.2% of total adjudications. Conclusions: We provide baseline performances for monitoring reader performance in trials with double reads. Intelligent reading system implementation along with appropriate reader training and monitoring are solutions that could mitigate a large portion of the commonly encountered reading errors. MDPI 2021-09-09 /pmc/articles/PMC8465869/ /pubmed/34572761 http://dx.doi.org/10.3390/cancers13184533 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Beaumont, Hubert
Iannessi, Antoine
Wang, Yi
Voyton, Charles M.
Cillario, Jennifer
Liu, Yan
Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials
title Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials
title_full Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials
title_fullStr Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials
title_full_unstemmed Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials
title_short Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials
title_sort blinded independent central review (bicr) in new therapeutic lung cancer trials
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465869/
https://www.ncbi.nlm.nih.gov/pubmed/34572761
http://dx.doi.org/10.3390/cancers13184533
work_keys_str_mv AT beaumonthubert blindedindependentcentralreviewbicrinnewtherapeuticlungcancertrials
AT iannessiantoine blindedindependentcentralreviewbicrinnewtherapeuticlungcancertrials
AT wangyi blindedindependentcentralreviewbicrinnewtherapeuticlungcancertrials
AT voytoncharlesm blindedindependentcentralreviewbicrinnewtherapeuticlungcancertrials
AT cillariojennifer blindedindependentcentralreviewbicrinnewtherapeuticlungcancertrials
AT liuyan blindedindependentcentralreviewbicrinnewtherapeuticlungcancertrials